Release date: 2016-07-19 Recently, the US FDA announced the approval of the Tecnis Symfony intraocular lens developed by Abbott Medical Optics for the treatment of cataract patients. It is worth mentioning that this is the first “continuous line of sight†intraocular lens approved by the FDA, which can effectively improve the patient's vision at close, intermediate and long distances. Tecnis Symfony intraocular lens significantly improves vision at various distances Cataract is a very common eye disease. With age, the patient's lens will gradually become cloudy, which seriously affects vision. According to statistics, more than 20% of people in the US over 65 years of age will develop cataract symptoms. As you get older, the proportion of people with cataracts increases. In China, cataract is the most common eye disease with a blindness rate of up to 47%. As the Chinese population ages, the number of cataract patients will remain high in the future. Currently, the usual treatment for cataracts is to perform surgery to remove the turbid natural lens and implant the intraocular lens. However, the conventional intraocular lens has a single focus point and there is a problem of visual distance. The patients also have to wear glasses to see things in the distance and near, which causes considerable inconvenience to their lives. Mechanism of action of Tecnis Symfony intraocular lens The approved Tecnis Symfony continuous line of sight intraocular lens is expected to reverse this situation. The lens has an innovative design that creates a new diffraction pattern of light that ultimately extends the line of sight. In a large clinical trial involving 299 people, 148 cataract patients underwent a new intraocular lens implantation, and 151 patients used a conventional lens. The results showed that the former had significantly improved visual acuity at close, medium and long distances - 77% of cataract patients could see the medium distance object without the use of glasses after using the new lens, and this number is in the conventional lens. The proportion of recipients is only 34%; the former can see more words on the two lines of the eye chart than the latter; they are also more sensitive to changes in the contrast of the light. Dr. Malvina Eydelman "Intraocular lens implantation has been the mainstream method of cataract treatment, but we are still looking for breakthroughs in this technology," said Dr. Malvina Eydelman, head of the FDA's eye, ear, nose and throat instrument. "This continuous line of IOL is for patients. Provides a new treatment regimen that promises to maintain good vision across all line of sight." It is worth mentioning that the product has submitted a listing application to the State Administration of Food, Drug Administration and has been approved. We wish it will benefit the vast majority of cataract patients in China. Source: WuXi PharmaTech plasticizer Shandong YingLang Chemical Co.,Ltd , https://www.sdylhgtrade.com